News Details

( 08/06/2018 15:04)
Cipla partners with Eli Lilly to market diabetes drug Basaglar in India

Drug firm Cipla today said it has partnered with Eli Lilly to market and distribute Lilly's insulin glargine injection, Basaglar, in India.

Cipla's tie up is with Eli Lilly and Company (India) Pvt Ltd, a 100 per cent subsidiary of the US based firm, the two firms said in a joint statement.

The companies did not disclose the financial details of the deal.

Cipla expects to start commercialising Basaglar in India by end of this year.

Cipla MD & Global CEO Umang Vohra said: "Diabetes continues to be a focus area for Cipla and with the launch of strong brand like Basaglar, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables."

The company's focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication, he added.

Lilly India MD Luca Visini said: "This strategic partnership leverages Lilly's commitment to bring innovation to people suffering from diabetes in India and Cipla's strong on-ground footprint across the country."

ATTENTION INVESTORS 1 : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case | 2 : "Prevent Unauthorized Transactions in your demat / trading account --> Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors. | 3 : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

SEBI Regn. NSE: INB231280430 I F&O: INF231280430 I BSE: INB011280436 I NSE CD: INE231280430 I MCX-SX: INE261280430

Copyright © 2017 Rikhav Securities Ltd. All rights reserved

Designed , Developed & Content Powered by DION